ARTICLE | Clinical News

Retaspimycin: Phase I data

June 9, 2008 7:00 AM UTC

In an open-label, U.S. and Canadian Phase I trial of IPI-504 in 36 evaluable patients, there was one partial response and 24 cases of disease stabilization at 6 weeks. Median PFS was 12 weeks. The max...